Apple Inc. (AAPL) shocked investors when the company pre-released its fiscal first quarter revenue, noting it would come in lower than previous guidance. The news sent shares sharply lower, plunging 10% on January 3. Through January 4, Apple’s stock has now fallen 36% from its October highs.

Not all investors were caught off guard by the recent declines though, as hedge funds were actively selling the phone maker in the third quarter. Investors’ worries have centered around the trade war’s potential impact on Apple and fears of declining iPhone sales. In September, Apple hosted an annual event revealing its latest iPhone models.

The stock market slide has gone from bad to worse over the past few weeks. Major indexes such as the Russell 2000 and the NASDAQ composite are now in a bear market, down more than 20%. Meanwhile, the S&P 500 and Dow Jones Industrial Average have fallen 16 and 17% respectively. Surprisingly, hedge funds and institutions may not have seen this sudden downturn coming.

The shares of Acadia Pharmaceuticals, Inc. (ACAD) have plunged 40% in 2018. Still, it did not stop the Baker Brothers Advisors L.P. from sharply increasing their holdings in the stock when they had the opportunity. The company filed a $200 million secondary offering on November 26 to raise additional capital as they continue to grow.  The company’s lead drug is NUPLAZID, which is the only drug approved for the treatment of Parkinson disease psychosis.

Amgen, Inc.’s (AMGN) stock has been hot since the end of the third quarter, rising about 1%. It does not sound impressive, but then again the broader S&P 500 has fallen 5% over the same time, while the iShares NASDAQ Biotechnology ETF (IBB) has fallen 11%. The recent rise in the stock should not be […]

Nvidia Corp.’s (NVDA) stock had been one of the great growth stories in the stock market over the past five years. The stock has surged by more than tenfold during that time. However, that has all come to a halt since October with the stock crashing,  now 43% off its highs. The bad news is that hedge funds and institutions had been buying up shares of the stock and the third quarter was no different.